⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0002123881

Teyssedou Lenaic Nathanael

Reports to the SEC for 1 company · GENEVA

Transactions

16

Companies

1

Filings

1

CIK

0002123881

Forms 4 and 5

Insider transactions

16 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−37.8K sh	—	—	565,138
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+37.8K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−59.5K sh	—	—	543,378
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+59.5K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−10K sh	—	—	592,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+10K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−30K sh	—	—	572,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+30K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−65.6K sh	—	—	537,288
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+65.6K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−90.5K sh	—	—	512,379
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+90.5K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−209K sh	—	—	393,934
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+209K sh	—	—	602,908
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)D Disposition to Issuer	PRINCIPAL ACCOUNTING OFFICER	DDisposition to Issuer	−100K sh	—	—	502,423
2026-09-02	ADXNAddex Therapeutics Ltd. · Stock-option (Right to Buy)A Award	PRINCIPAL ACCOUNTING OFFICER	AAward	+100K sh	—	—	602,908

Recent filings

1

Accepted (ET)
Sep 44
Teyssedou Lenaic Nathanael0001104659-26-105509
SEC(opens sec.gov)

Companies

1

Addex Therapeutics Ltd.PRINCIPAL ACCOUNTING OFFICERADXN

Address

CHEMIN DES MINES 9

GENEVA, CH-1202